Zhitong Finance App News, Baiyunshan (00874) issued an announcement. Recently, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as “Mingxing Pharmaceutical”), a wholly-owned subsidiary of the company, received a “Pharmaceutical Production License” approved and issued by the Guangdong Drug Administration, agreeing that Mingxing Pharmaceutical will add a new production address, production scope, production workshop and production line, and pass a compliance inspection with pharmaceutical production quality management standards.

This time, Mingxing Pharmaceutical added a new production address, production scope, production workshop and production line, and passed compliance checks with pharmaceutical production quality management standards, which helps it optimize production capacity, improve the level of intelligence and digitalization, and continue to maintain stable production capacity to meet market demand. The “Pharmaceutical Production License” was obtained this time, and there was no significant impact on the company's current performance.